Recent Updates — ESTA

Establishment Labs Holdings reported third-quarter revenue of $72.0 million, a 33.9% increase from the prior year period, driven by 119% U.S. growth. The company achieved its first quarter of positive operating and free cash flow, with adjusted EBITDA rising to $6.4 million. Management raised full-year revenue guidance to more than $274 million, up from the previous range of $269 million to $271 million, while maintaining expectations for positive adjusted EBITDA for the fiscal year. The company operates in the medical device industry, specializing in breast aesthetics and reconstruction solutions.

Establishment Labs Holdings Inc. reported second quarter 2026 financial results with revenue of $67.5 million, a 31.7% increase from the prior year period. The company raised its full-year revenue guidance to $269 million–$271 million from the previous range of $266.5 million–$268.5 million. Adjusted EBITDA turned positive at $3.7 million, compared to a loss of $8.5 million in the year-ago quarter, while net loss narrowed to $11.7 million from $16.6 million. Cash balances stood at $71.2 million as of June 30, 2026. Establishment Labs Holdings Inc. operates in the medical device industry, specializing in breast aesthetics and reconstruction solutions.

Establishment Labs Holdings Inc. announced the appointment of Taylor Harris to its Board of Directors, effective June 24, 2026. Mr. Harris will serve until the 2027 annual meeting and will join the Audit Committee and the Nominating and Corporate Governance Committee. The company's non-employee director compensation policy, updated in April 2026, provides for an initial equity grant of $170,000 for new directors. Establishment Labs Holdings Inc. operates in the medical aesthetics industry, providing breast implants and related products.